NASDAQHealth CareBiotechnologySnapshot 2026-08-31
Reading MRNA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Broken: Primary pillar broken — Achieve up to 10% revenue growth in 2026: FY26 revenue guidance $1.1B vs FY25 $1.9B (-42%) vs 10% target.
Moderna aims for up to 10% revenue growth in 2026. It plans to keep a strong cash position near $7.5 billion. The company is expanding its mRNA platform and launching new vaccines. These moves could help it recover from recent losses.
Moderna is losing money and cut its guidance recently. Operating costs rose sharply to $1.8 billion in Q1 2026. FDA scrutiny may delay key product approvals. These issues could hurt growth and cash flow.
The price is about 37% above our fair value near $58. Analysts expect 9% revenue growth. We see risks from losses and cost pressures not fully priced in.
Breaks if: Cash and investments fall below 7.0 billion USD
Breaks if: Operating expenses rise above 1.8 billion USD per quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. MRNA is currently navigating a weak financial performance while aiming for revenue growth and managing costs.
The market seems to assume a high valuation despite MRNA's loss-making status and recent weak results. There is an expectations gap, indicating that investors may not fully appreciate the challenges ahead.
Management is focused on achieving revenue growth of up to 10% in 2026, but recent performance has been weak. The company's cash position is mixed, and while operating expenses are being managed, the overall financial trajectory remains uncertain.
The long-term thesis hinges on the ability to maintain revenue growth targets and manage costs effectively. Additionally, the performance of sector peers and overall economic conditions will play a crucial role in MRNA's future.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The FDA approved updated COVID-19 vaccines from Moderna, enhancing growth prospects. However, weaker vaccine uptake has led to expectations of lower demand for these vaccines.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Moderna is focused on reducing GAAP operating expenses in 2026.
Breaks if: Operating margin falls below 4.2 billion USD in FY26
Moderna is focused on reducing GAAP operating expenses in 2026.
Breaks if: YoY revenue growth falls below ~9% in FY26
Overall, MRNA's situation is complex, with both opportunities and risks ahead. Not investment advice.
